Fendiline

Fendiline

Clinical data
ATC code	C08EA01 ( WHO )
Identifiers
IUPAC name 3,3-diphenyl-N-(1-phenylethyl)propan-1-amine
CAS Number	13042-18-7  Y
PubChem CID	3336
DrugBank	DB08980  N
ChemSpider	3219  N
UNII	S253D559A8
KEGG	D07185  Y
ChEMBL	ChEMBL254832  N
CompTox Dashboard (EPA)	DTXSID5048473
ECHA InfoCard	100.032.635
Chemical and physical data
Formula	C23H25N
Molar mass	315.460 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(NCCC(c1ccccc1)c2ccccc2)c3ccccc3
InChI InChI=1S/C23H25N/c1-19(20-11-5-2-6-12-20)24-18-17-23(21-13-7-3-8-14-21)22-15-9-4-10-16-22/h2-16,19,23-24H,17-18H2,1H3 N Key:NMKSAYKQLCHXDK-UHFFFAOYSA-N N
NY  (what is this?)    (verify)

Fendiline is a nonselective calcium channel blocker and coronary vasodilator, originally developed for its anti-anginal and antiarrhythmic properties in the management of coronary heart disease. ^{[1] [2] [3]}

By inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells, fendiline promotes vasodilation, particularly of the coronary arteries, thereby increasing blood flow to the heart muscle, alleviating ischemia, and reducing chest pain associated with angina. ^[2] Although its clinical use has become limited due to the availability of alternative treatments and its relatively slow onset of action, fendiline remains notable for its long half-life, lack of tolerance development, and demonstrated efficacy in improving exercise tolerance and reducing the frequency of angina attacks in placebo-controlled trials. ^[2]

References

1. "Fendiline". DrugBank.
2. Bayer R, Mannhold R (1987). "Fendiline: a review of its basic pharmacological and clinical properties". Pharmatherapeutica. 5 (2): 103–136. OCLC   115670794. PMID   3310016.
3. Scultéty S, Tamáskovits E (1991). "Effect of Ca2+ antagonists on isolated rabbit detrusor muscle". Acta Physiologica Hungarica. 77 (3–4): 269–278. PMID   1755331.

Further reading

• Huang C, Huang C, Cheng J, Liu S, Chen I, Tsai J, et al. (January 2009). "Fendiline-evoked [Ca2+]i rises and non-Ca2+-triggered cell death in human oral cancer cells". Human & Experimental Toxicology. 28 (1): 41–48. Bibcode:2009HETox..28...41H. doi:10.1177/0960327108097436. PMID   19411560.
• Jan CR, Lee KC, Chou KJ, Cheng JS, Wang JL, Lo YK, et al. (July 2001). "Fendiline, an anti-anginal drug, increases intracellular Ca2+ in PC3 human prostate cancer cells". Cancer Chemotherapy and Pharmacology. 48 (1): 37–41. doi:10.1007/s002800000262. PMID   11488522.
• Kukovetz WR, Brunner F, Beubler E, Weyhenmeyer R, Lohaus R, Grob M, et al. (April 1982). "Single dose pharmacokinetics of fendiline in humans". European Journal of Drug Metabolism and Pharmacokinetics. 7 (2): 105–110. doi:10.1007/BF03188726. PMID   7117293.
• Lin MC, Jan CR (July 2002). "The anti-anginal drug fendiline elevates cytosolic Ca2+ in rabbit corneal epithelial cells". Life Sciences. 71 (9): 1071–1079. doi:10.1016/S0024-3205(02)01797-6. PMID   12088766.
• van der Hoeven D, Cho KJ, Ma X, Chigurupati S, Parton RG, Hancock JF (2013). "Fendiline Inhibits K-Ras Plasma Membrane Localization and Blocks K-Ras Signal Transmission". Molecular and Cellular Biology. 33 (2): 237–251. doi:10.1128/MCB.00884-12. PMC   3554123 . PMID   23129805.
• Woods N, Trevino J, Coppola D, Chellappan S, Yang S, Padmanabhan J (3 November 2015). "Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling". Oncotarget. 6 (34): 35931–35948. doi:10.18632/oncotarget.5933. PMC   4742152 . PMID   26440150.